MOLN

Molecular Partners

4.20 USD
+0.12
2.94%
At close Apr 25, 4:00 PM EDT
After hours
5.10
+0.90
21.43%
1 day
2.94%
5 days
0.96%
1 month
8.25%
3 months
-20.90%
6 months
-35.29%
Year to date
-13.76%
1 year
8.25%
5 years
-78.63%
10 years
-78.63%
 

About: Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Employees: 159

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

306% more capital invested

Capital invested by funds: $4.2M [Q3] → $17M (+$12.8M) [Q4]

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

6.56% more ownership

Funds ownership: 2.31% [Q3] → 8.88% (+6.56%) [Q4]

0% more funds holding

Funds holding: 5 [Q3] → 5 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$12
186%
upside
Avg. target
$12
186%
upside
High target
$12
186%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
LifeSci Capital
186%upside
$12
Outperform
Initiated
11 Mar 2025

Financial journalist opinion

Based on 3 articles about MOLN published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of three posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30 in Chicago, IL. The first poster includes positive Investigational New Drug (IND)-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb for small cell lung cancer patients. The second poster presents initial preclinical data on the second 212Pb-based Radio-DARPin, targeting mesothelin (MSLN) in solid tumors – both programs are co-developed with Orano Med. The third poster includes additional preclinical proof-of-concept data on the logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors.
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
Neutral
GlobeNewsWire
1 week ago
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority.
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
Neutral
Zacks Investment Research
3 weeks ago
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Molecular Partners AG Sponsored ADR (MOLN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher
Neutral
GlobeNewsWire
1 month ago
Molecular Partners to hold three poster presentations at AACR 2025
Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer
Molecular Partners to hold three poster presentations at AACR 2025
Neutral
GlobeNewsWire
1 month ago
Molecular Partners Publishes Invitation to Annual General Meeting 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2025.
Molecular Partners Publishes Invitation to Annual General Meeting 2025
Neutral
Seeking Alpha
1 month ago
Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript
Molecular Partners AG (NASDAQ:MOLN ) Q4 2024 Earnings Conference Call March 7, 2025 8:00 AM ET Company Participants Michael Tobias Stumpp - EVP Projects Patrick Amstutz - Co-Founder & CEO Philippe Legenne - Chief Medical Officer Robert Hendriks - SVP Finance Seth Lewis - SVP Investor Relations, Communications and Strategy Conference Call Participants Jonathan Chang - Leerink Partners Richard Vosser - JPMorgan Michael Nedelcovych - TD Cowen Joris Zimmermann - Octavian Operator Good morning, and welcome to the Molecular Partners Fourth Quarter and Full Year 2024 Results Call. All participants will be in listen-only mode.
Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced its corporate highlights and audited financial results for the full year 2024, as well as the publication of its 2024 Annual Report.
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
Neutral
GlobeNewsWire
1 month ago
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences.
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
Positive
Seeking Alpha
3 months ago
Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs
Molecular Partners AG leverages a novel DARPin platform for targeted cancer therapies, with promising early-stage candidates like MP0533 and MP0317 in clinical trials. Financially, MOLN has a cash runway of 2-2.5 years, but future funding remains uncertain, posing a risk for long-term sustainability. Strengths include innovative approaches and a diverse pipeline, but the lack of a clear frontrunner and early-stage focus are significant risks.
Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs
Neutral
GlobeNewsWire
3 months ago
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a clinical-stage radiopharmaceutical company and a pioneer in the development of targeted alpha-particle therapies (TAT) with 212Pb (lead-212), today announced the expansion of their strategic collaboration.
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
Charts implemented using Lightweight Charts™